SNPMiner Trials (Home Page)
Report for Clinical Trial NCT03622580
 Developed by Shray Alag, 2020-2021.
SNP Clinical Trial Gene 
      This study will evaluate the efficacy, safety, and pharmacokinetics of faricimab administered
      at 8-week intervals or as specified in the protocol following treatment initiation, compared
      with aflibercept once every 8 weeks (Q8W), in participants with diabetic macular edema (DME).
    
Name: Aflibercept
Description: Aflibercept will be administered by intravitreal (IVT) injection into the study eye once every 8 weeks (Q8W).
 Type: Drug
Group Labels:  1  C: Aflibercept Q8W  
 Name: Faricimab
Description: Faricimab will be administered by IVT injection into the study eye either once every 8 weeks (Q8W) in arm A or as specified in the protocol in arm B.
 Type: Drug
Group Labels:  2  A: Faricimab Q8W  B: Faricimab As Specified in Protocol  
 Name: Sham Procedure
Description: The sham is a procedure that mimics an IVT injection and involves the blunt end of an empty syringe (without a needle) being pressed against the anesthetized eye. It will be administered to participants in all three treatments arms at applicable clinic visits to maintain masking among treatment arms.
 Type: Drug
Group Labels:  3  A: Faricimab Q8W  B: Faricimab As Specified in Protocol  C: Aflibercept Q8W  
  Primary Outcomes 
 Description: As measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters.
 Measure: Average Change From Baseline in Best-Corrected Visual Acuity (BCVA) at 1 Year
 Time: Baseline (Day 1) and 1 year
    
Secondary Outcomes 
 Measure: Percentage of Participants with a ≥2-Step Diabetic Retinopathy Severity (DRS) Improvement From Baseline on the ETDRS Diabetic Retinopathy Severity Scale (DRSS) at 1 Year Time: Baseline and 1 year
 Measure: Change From Baseline in BCVA Over Time Time: From Baseline up to 2 years
 Measure: Percentage of Participants Gaining ≥15 Letters in BCVA From Baseline Over Time Time: From Baseline up to 2 years
 Measure: Percentage of Participants Gaining ≥10 Letters in BCVA From Baseline Over Time Time: From Baseline up to 2 years
 Measure: Percentage of Participants Gaining ≥5 Letters in BCVA From Baseline Over Time Time: From Baseline up to 2 years
 Measure: Percentage of Participants Gaining ≥0 Letters in BCVA From Baseline Over Time Time: From Baseline up to 2 years
 Measure: Percentage of Participants Avoiding a Loss of ≥15 Letters in BCVA From Baseline Over Time Time: From Baseline up to 2 years
 Measure: Percentage of Participants Avoiding a Loss of ≥10 Letters in BCVA From Baseline Over Time Time: From Baseline up to 2 years
 Measure: Percentage of Participants Avoiding a Loss of ≥5 Letters in BCVA From Baseline Over Time Time: From Baseline up to 2 years
 Measure: Percentage of Participants Avoiding a Loss of >0 Letters in BCVA From Baseline Over Time Time: From Baseline up to 2 years
 Measure: Percentage of Participants Gaining ≥15 Letters or Achieving BCVA of ≥84 Letters Over Time Time: Up to 2 years
 Measure: Percentage of Participants with BCVA Snellen Equivalent of 20/40 or Better Over Time Time: Up to 2 years
 Measure: Percentage of Participants with BCVA Snellen Equivalent of 20/200 or Worse Over Time Time: Up to 2 years
 Measure: Percentage of Participants with a ≥2-Step DRS Improvement From Baseline on the ETDRS DRSS Over Time Time: From Baseline up to 2 years
 Measure: Percentage of Participants with a ≥3-Step DRS Improvement From Baseline on the ETDRS DRSS Over Time Time: From Baseline up to 2 years
 Measure: Percentage of Participants Who Develop New Proliferative Diabetic Retinopathy Over Time Time: Up to 2 years
 Measure: Percentage of Participants in the Faricimab As Specified in Protocol Arm on a Q4W, Q8W, Q12W, or Q16W Treatment Interval at 1 Year Time: 1 year
 Measure: Percentage of Participants in the Faricimab As Specified in Protocol Arm on a Q4W, Q8W, Q12W, or Q16W Treatment Interval at 2 Years Time: 2 years
 Measure: Change From Baseline in Central Subfield Thickness Over Time Time: From Baseline up to 2 years
 Measure: Change From Baseline in Central Subfield Thickness at 1 Year Time: Baseline and 1 year
 Measure: Percentage of Participants with Absence of DME Over Time Time: Up to 2 years
 Measure: Percentage of Participants with Absence of Intraretinal Fluid Over Time Time: Up to 2 years
 Measure: Percentage of Participants with Absence of Subretinal Fluid Over Time Time: Up to 2 years
 Measure: Percentage of Participants with Absence of Intraretinal Fluid and Subretinal Fluid Over Time Time: Up to 2 years
 Measure: Change From Baseline in National Eye Institute Visual Functioning Questionnaire-25 (NEI VFQ-25) Composite Score Over Time Time: From Baseline up to 2 years
 Measure: Percentage of Participants with At Least One Ocular Adverse Event Time: Up to 2 years
 Measure: Percentage of Participants with At Least One Non-Ocular Adverse Event Time: Up to 2 years
 Measure: Plasma Concentration of Faricimab Over Time Time: Pre-dose on Day 1; Weeks 4, 28, 52, 76, and 100; and at Early Termination Visit (up to 2 years)
 Measure: Percentage of Participants with Presence of Anti-Drug Antibodies Time: Pre-dose on Day 1; Weeks 4, 28, 52, 76, and 100; and at Early Termination Visit (up to 2 years)
 
Purpose: Treatment
Allocation: Randomized
Parallel Assignment 
There are 2 SNPs
SNPs
1 Q12W 
Percentage of Participants in the Faricimab As Specified in Protocol Arm on a Q4W, Q8W, Q12W, or Q16W Treatment Interval at 1 Year. --- Q12W --- 
Percentage of Participants in the Faricimab As Specified in Protocol Arm on a Q4W, Q8W, Q12W, or Q16W Treatment Interval at 2 Years. --- Q12W --- 
 Percentage of Participants in the Faricimab As Specified in Protocol Arm on a Q4W, Q8W, Q12W, or Q16W Treatment Interval at 1 Year. --- Q12W ---  --- Q16W --- 
Percentage of Participants in the Faricimab As Specified in Protocol Arm on a Q4W, Q8W, Q12W, or Q16W Treatment Interval at 2 Years. --- Q12W ---  --- Q16W ---